[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567754":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":10,"centralContacts":22,"locations":28,"responsibleParty":62,"collaborators":10,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":10,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":10,"enrollmentInfo":73,"targetDuration":10,"studyType":76,"phases":10,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"EXoPERT","INDUSTRY",[8,13],{"label":9,"type":10,"description":10,"interventionNames":11},"Breast malignant nodule group",null,[12],"Diagnostic Test: ExoPred",{"label":14,"type":10,"description":10,"interventionNames":15},"Breast benign nodule group",[12],[17],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":10},"DIAGNOSTIC_TEST","ExoPred","Performing in vitro diagnostics with devices developed by EXoPERT",[14,9],[23],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"Jongwon Choi","CONTACT","+82-10-3931-2941","necain1003@exopert.com",[29,51],{"facility":30,"status":31,"city":32,"state":10,"zip":10,"country":33,"countryCode":10,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Korea University Anam Hospital","RECRUITING","Seoul","South Korea",{"type":35,"coordinates":36},"Point",[37,38],126.9784,37.566,{"lat":38,"lon":37},[41,45,48],{"name":42,"role":25,"phone":43,"phoneExt":10,"email":44},"Dongwon You","+82-10-3062-8833","dwyou@exopert.com",{"name":46,"role":47,"phone":10,"phoneExt":10,"email":10},"Seungpil Jung, MD","PRINCIPAL_INVESTIGATOR",{"name":49,"role":50,"phone":10,"phoneExt":10,"email":10},"Sung Eun Song, MD","SUB_INVESTIGATOR",{"facility":52,"status":31,"city":32,"state":10,"zip":10,"country":33,"countryCode":10,"cosmosGeoPoint":53,"geoPoint":55,"contacts":56},"Korea University Guro Hospital",{"type":35,"coordinates":54},[37,38],{"lat":38,"lon":37},[57,58,60],{"name":42,"role":25,"phone":43,"phoneExt":10,"email":44},{"name":59,"role":47,"phone":10,"phoneExt":10,"email":10},"Wooyoung Kim, MD",{"name":61,"role":50,"phone":10,"phoneExt":10,"email":10},"Ok-hee Woo, MD",{"type":63,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100567754","a-prospective-study-to-develop-and-clinically-validate-an-in-vitro-diagnostic-medical-device-that-uses-blood-to-classify-patients-at-high-risk-for-breast-cancer-100567754",false,"NCT06672302","A Prospective Study to Develop and Clinically Validate an in Vitro Diagnostic Medical Device That Uses Blood to Classify Patients at High Risk for Breast Cancer","A Multi-center, Single Arm, Prospective Exploratory in Vitro Diagnostic Devices Clinical Performance Study to Evaluate of in Vitro Diagnostic Devices for Auxiliary Diagnosis That Classifies High-risk and Low Risk Patients With Breast Cancer by Analyzing Surface-enhanced Raman Spectroscopy (SERS) Profiles of Extracellular Vesicles (EVs) Extracted From Human Plasma Using Artificial Intelligence","Inclusion Criteria(Breast malignant nodule group)\n\n1. Korean nationality\n2. Voluntary written consent to participate in this clinical performance trial study\n3. Confirmed breast cancer through imaging\u002Fpathologic diagnostic tests\n4. Those who have been diagnosed with breast cancer at a stage prior to treatment and surgery, and who agree to participate in this study and are able to provide blood samples.\n5. Those whose lesions have been confirmed by conventional examination (breast ultrasound or mammography) and who fall into BI-RADS categories 4,5,6 and have undergone biopsy or are scheduled to undergo biopsy within 2 weeks.\n6. Those who meet the following demographic conditions A. Adult female, 40 years of age or older\n7. Those who can provide the following clinical information A. Age and biological sex B. Whether or not they have dense breasts C. Occupational information D. Pathological tumor size, Clinical tumor size, Pathological TNM staging, Clinical TNM staging, tumor location, breast cancer histology findings (breast cancer subtype) E. Family history and past history of cancer F. Breast-related diseases G. Chronic disease history\n\nInclusion Criteria(Breast benign nodule group)\n\n1. Korean nationality\n2. Voluntary written consent to participate in this clinical performance trial study\n3. Diagnosed with breast nodules through imaging\u002Fpathologic diagnostic tests\n4. Those who have been diagnosed with breast nodules and have agreed to participate in this study and are able to provide blood samples at a stage prior to treatment and surgery.\n5. Those whose lesions have been confirmed by conventional examination (breast ultrasound or mammography) and fall into BI-RADS categories 4,5,6 and have undergone biopsy or are scheduled for biopsy within 2 weeks\n6. Those who meet the following demographic conditions A. Adult female, 40 years of age or older\n7. Those who can provide the following clinical information A. Age and biological sex B. Whether or not they have dense breasts C. Occupational information D. Diagnosis, nodule size, and number of nodules E. Family history and past history of cancer F. Breast-related diseases G. Chronic disease history\n\nExclusion Criteria:\n\n1. Those who have been diagnosed with cancer (malignant tumor) of any type within 5 years of the date of consent and have undergone appropriate chemotherapy\u002Fradiation treatment or surgery.\n2. Those who are confirmed to have developed breast cancer due to metastasis from malignant tumors other than breast cancer\n3. Pregnant women\n4. Participation in a drug-related clinical trial within 3 months of the date of the informed consent form","FEMALE","40 Years",{"count":74,"type":75},330,"ESTIMATED","OBSERVATIONAL","EXoPERT has developed a liquid biopsy-based in vitro diagnostic medical device that can diagnose cancer through blood. The in vitro diagnostic medical device for this clinical performance trial is a test device that applies a technology that measures Raman spectroscopic signals of extracellular vesicles in the blood and classifies high-risk and low-risk patients for breast cancer through artificial intelligence analysis.\n\nThe test device used in this clinical performance trial is expected to assist in the differential diagnosis of high-risk and low-risk breast cancer patients by developing a software algorithm for an in vitro diagnostic medical device for auxiliary diagnosis that classifies high-risk and low-risk breast cancer patients and confirming the clinical efficacy and safety of the device through this clinical performance trial.",[79],"Breast Neoplasm",[81,82,83],"Breast","Breast Cancer","Neoplasm","2026-01-06",{"date":86,"type":87},"2026-01-08","ACTUAL",{"date":89,"type":87},"2024-10-16",{"date":91,"type":75},"2026-12-31",{"name":5,"class":6},2]